Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App





Nano-Laser Technology Could Eliminate Coronavirus from Bodies of COVID-19 Patients

By HospiMedica International staff writers
Posted on 22 Jul 2020
A patent pending treatment aims to use laser technology to eradicate the COVID-19 coronavirus by introducing one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., COVID-19 target antigens).

The technology has been developed by Halberd Corp. More...
(Jackson Center, PA, USA) and will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the removal of the debris through conventional mechanical filtering. The method entails the extracorporeal (outside the body) treatment of a patient's blood (for blood-borne diseases) or cerebrospinal fluid (CSF - for neurological diseases) consisting of a four-step process, including removal of bodily fluid from the patient; introduction of antibody-antigen complexing agent(s) to bind with the target antigen(s) (i.e., COVID-19 target antigens), eradicate the fluoresced antibody-antigen complex with a nano-laser and removal of the debris; and return of the cleansed bodily fluid to the patient.

This process is intended to be performed during a continuous-flow operation, similar to normal dialysis. By treating the blood or CSF outside of the patient, and using complexing agents which combine only with antigens associated with COVID-19, negative side-effects and reactions can be greatly reduced or eliminated.

“This process is intended to eliminate COVID-19 coronavirus, and its mutations from a patient's body. The use of a nano-laser and the associated complex computer controlled targeting system, should allow for a great flexibility in selecting and eliminating disease antigens, said Dr. Mitchell S. Felder, who invented the treatment.

“COVID-19 is a complex and virulent virus. We decided to pursue several alternatives of varying complexities in an attempt to address the complete elimination of the virus, and to develop an effective treatment protocol,” said William A. Hartman, Chairman, President & CEO of Halberd Corporation.

Related Links:
Halberd Corp.


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Spirometry & Oximetry Software
MIR Spiro
Radiology System
Riviera SPV AT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.